Helicobacter pylori was discovered in 1983 when Barry Marshall and Robin Warren — who shared the 2005 Nobel Prize in Physiology or Medicine for the discovery — cultured a previously unknown spiral-shaped gram-negative bacterium from gastric biopsy samples. Marshall famously drank a petri dish containing H. pylori culture to prove Koch's postulates, developing acute gastritis within days and resolving it with bismuth and metronidazole. The discovery overturned decades of medical consensus that peptic ulcer disease was caused by stress, spicy food, and excess acid production — when in fact 80–90% of duodenal ulcers and 70–80% of gastric ulcers are caused by H. pylori infection.
H. pylori is a uniquely evolved human pathogen. Unlike most bacteria, it thrives in the highly acidic environment of the gastric mucosa (pH 1.5–3.5) by producing large quantities of urease enzyme, which hydrolyzes urea to ammonia and CO₂ — locally neutralizing the pH around the bacterium and creating a protective alkaline microenvironment. The organism then adheres to gastric mucous epithelial cells using multiple adhesins (BabA binds to the Lewis b blood group antigen on epithelial cells; OipA and SabA bind to additional epithelial surface antigens) and evades the immune response via multiple mechanisms including LPS modification to reduce TLR4 activation. What makes some H. pylori strains particularly dangerous is the CagA pathogenicity island (PAI) — a 40-kilobase genomic region encoding a Type IV secretion system that injects the CagA oncoprotein directly into host gastric epithelial cells.
CagA Virulence + Cancer Risk
the mechanism of carcinogenesis: CAGA PATHOGENICITY ISLAND: approximately 60–70% of H. pylori strains in Western countries and up to 90% of strains in East Asia carry the cagA gene; the cagPAI encodes a Type IV secretion system (T4SS) — a molecular syringe that punctures the host epithelial cell membrane; CAGA INJECTION AND PHOSPHORYLATION: CagA protein is injected into gastric epithelial cells via the T4SS; once inside, CagA is phosphorylated by host Src kinases on its EPIYA (Glu-Pro-Ile-Tyr-Ala) motifs (East Asian strains have more EPIYA-C repeats than Western strains → more phosphorylation sites → more oncogenic activity); CAGA DOWNSTREAM SIGNALING: phosphorylated CagA binds and activates SHP-2 (Src homology-2 phosphatase) → normally a growth factor receptor regulator; aberrant SHP-2 activation → dysregulates ERK/MAPK, PI3K/Akt, and Wnt/β-catenin pathways → promotes cell proliferation, suppresses apoptosis, and disrupts cell polarity (loss of contact inhibition); CagA also activates NF-κB → chronic inflammation → IL-8, IL-12, TNF-α → recruits neutrophils and macrophages → generates ROS → DNA damage; CagA has been called a "bacterial oncoprotein" — it is functional as a human oncogene in transgenic mice that overexpress it; GASTRIC CANCER RISK STRATIFICATION: H. pylori infection without CagA: ~3–5× increased gastric adenocarcinoma risk vs uninfected; H. pylori CagA+ infection: ~10–15× increased risk; H. pylori CagA+ with virulent EPIYA-C repeats (East Asian strains): up to 20-30× risk in some epidemiological studies; the Correa cascade from H. pylori → chronic active gastritis → atrophic gastritis → intestinal metaplasia → dysplasia → adenocarcinoma typically takes decades; gastric cancer from H. pylori is the third leading cause of cancer death worldwide (IARC, 2020); IARC GROUP I DESIGNATION: in 1994, the IARC (International Agency for Research on Cancer) classified H. pylori as a definitive Group I carcinogen — the same category as tobacco, asbestos, and aflatoxin; it is the only bacterial infection in Group I; VACA (vacuolating cytotoxin A): a second major virulence factor; VacA is a pore-forming toxin secreted by H. pylori (not injected); VacA creates anion-selective channels in the mitochondrial membrane → mitochondrial dysfunction → cytochrome c release → apoptosis of gastric epithelial cells; VacA also disrupts vacuolar ATPase → impairs lysosomal function → antigen presentation defect → immune evasion; s1m1 VacA genotype is the most virulent; strains with both CagA+ and s1m1 VacA have the highest cancer risk
Diagnosis: Test Comparison
what to use and when: FOUR DIAGNOSTIC APPROACHES: UBT (UREA BREATH TEST): principle: patient swallows 13C- or 14C-labeled urea; if H. pylori is present, its urease cleaves the labeled urea → labeled CO₂ in breath; sensitivity: 95–97%; specificity: 95–98%; non-invasive; requires stopping PPIs 2 weeks before (PPIs suppress H. pylori → false negative) and antibiotics 4 weeks before; gold standard for: initial diagnosis, post-treatment confirmation (≥4 weeks after treatment ends); STOOL ANTIGEN TEST (SAT): principle: immunoassay detects H. pylori antigens in stool; sensitivity: 94–96%; specificity: 93–96%; non-invasive; also requires PPI stop 2 weeks before; as accurate as UBT for both diagnosis and post-treatment confirmation; more convenient (no clinic visit needed); HpSA (H. pylori stool antigen) is FDA-cleared and guideline-recommended; ENDOSCOPY WITH BIOPSY: indications: needed for all patients ≥60 with alarm symptoms (dysphagia, weight loss, bleeding, vomiting); allows: (1) Rapid Urease Test (RUT) on fresh biopsy → most common in-clinic test; (2) Histopathology (gold standard for cancer screening, intestinal metaplasia assessment); (3) Culture + antibiotic susceptibility testing (AST) — the most important test in high-resistance areas to guide antibiotic selection; sensitivity of biopsy-based tests: ~90–95% but affected by biopsy site and PPI use; SEROLOGY (ANTI-H. PYLORI IgG): SHOULD NOT BE USED for: post-treatment confirmation (antibodies persist for years after successful eradication — no way to tell if current infection or past); preferred only in settings where UBT/SAT are unavailable; in the US with widespread UBT/SAT availability, serology is not appropriate for routine clinical use; sensitivity: 76–84%; positive predictive value is poor in low-prevalence populations; POST-TREATMENT TESTING IS MANDATORY: all patients treated for H. pylori should have eradication confirmed ≥4 weeks after completing treatment AND 2+ weeks after stopping PPIs; re-treatment with a different regimen is required if eradication is not confirmed; guideline recommendation: UBT or SAT for post-treatment confirmation; NEVER serology
Clarithromycin Resistance + New Guidelines
why triple therapy is obsolete and bismuth quadruple is now first-line: STANDARD TRIPLE THERAPY (the old standard): PPI + clarithromycin + amoxicillin × 7–14 days; was first-line globally from ~1996–2015; eradication rate when resistance was low (~<10%): ~80–85%; NOW OBSOLETE IN MOST REGIONS: CLARITHROMYCIN RESISTANCE RATES (ATLAS study, 2018, N=4,000+ isolates across Europe): UK: 29.9%; France: 31.4%; Italy: 30.0%; Germany: 22.2%; Spain: 28.4%; US: estimated 15–22% (regional variation); East Asia: 20–35% in many urban centers; China: up to 40%+ in some regions; when clarithromycin resistance exceeds 15%, standard triple therapy eradication falls below 80% (the minimum acceptable threshold); the 80% threshold is important: below it, empiric triple therapy causes more harm (antibiotic resistance amplification) than good; MAASTRICHT VI / TORONTO CONSENSUS (2022 update): current European and North American consensus: bismuth quadruple therapy is now first-line in regions with clarithromycin resistance ≥15%; triple therapy acceptable only where resistance remains below 15% (now rare); BISMUTH QUADRUPLE THERAPY (PYLERA or equivalent): components: bismuth subcitrate (or subsalicylate) 120–300mg QID + PPI BID + tetracycline 500mg QID + metronidazole 500mg TID; duration: 14 days; eradication rate: 85–95% even in clarithromycin-resistant strains (because none of the 4 drugs is clarithromycin); Pylera is a combination capsule (bismuth + tetracycline + metronidazole) + separate PPI; mechanism of bismuth: bismuth ions are directly bactericidal (damage H. pylori cell membrane, inhibit urease, disrupt ATP synthesis) independently of the antibiotics → provides redundancy against antibiotic-resistant strains; VONOPRAZAN (NEW): potassium-competitive acid blocker (P-CAB) that is more potent and faster than PPIs; vonoprazan-amoxicillin dual therapy: 93% eradication in Japan (Murakami 2020); may become a preferred regimen in antibiotic-minimizing frameworks; FDA approved in the US 2022 (Voquezna, Phathom); offers an antibiotic-sparing approach for penicillin-allergic patients or antibiotic-resistant regions when combined with clarithromycin or metronidazole
Probiotic Adjunct Evidence
how adding probiotics improves eradication rates and tolerability: RATIONALE FOR PROBIOTIC ADJUNCTION: H. pylori eradication antibiotics (especially metronidazole, tetracycline, amoxicillin) cause significant gut microbiome dysbiosis → C. diff risk, diarrhea, nausea → adherence drops → eradication fails; some probiotic strains directly inhibit H. pylori via: bacteriocin production (Lactobacillus), competitive adhesion to BabA receptor sites, urease inhibition by Lactobacillus metabolites (lactic acid reduces urease activity), immunomodulation (decreased TNF-α at gastric mucosa); OJETTI 2012 (the key adjunction RCT): Ojetti V et al. (2012, European Journal of Gastroenterology and Hepatology): triple therapy + L. reuteri DSM 17938 (BioGaia, 1×10⁸ CFU) vs triple therapy alone; N=70; primary endpoint: 13C-UBT eradication rate 4 weeks post-treatment; eradication rate: L. reuteri group: 84.6% vs control: 71.8% (p=0.045); adverse effects: control group: 32.4% vs L. reuteri: 12.8% (p<0.05); the +13 percentage point improvement in eradication rate is clinically meaningful; CUI 2019 COCHRANE META-ANALYSIS: Cui Y et al. (2019, Medicine): 40 RCTs, N=5,792 patients: probiotic supplementation with H. pylori eradication therapy: significantly higher eradication rate (OR 1.68, p<0.001); significantly lower adverse effects (OR 0.41, diarrhea; OR 0.24, nausea; OR 0.31, epigastric pain); SACCHAROMYCES BOULARDII AS ADJUNCT: Cindoruk 2007 (Dig Dis Sci, N=124): triple therapy + S. boulardii 500mg BID × 14 days: eradication 71.4% vs 60.5% (p=0.04), adverse effect rate significantly lower; S. boulardii is antibiotic-resistant (it is a yeast, not bacteria) → continues to colonize during the antibiotic treatment period → most effective adjunct; LACTOBACILLUS REUTERI + BB-12 COMBINATION: Francavilla 2013: multi-strain combination of L. reuteri DSM 17938 + BB-12 showed additive effects; PRACTICAL RECOMMENDATION: start probiotic at the same time as eradication therapy (not after): L. reuteri DSM 17938 (BioGaia) 1 tablet BID + S. boulardii (Florastor) 500mg BID; continue for 4 weeks total; separate probiotic from antibiotic by 2 hours (especially important for bacterial probiotics to avoid the antibiotic killing the probiotic before it can act)
| Regimen | Components | Duration | Eradication Rate | Use When |
|---|
| Bismuth Quadruple (Pylera) | Bismuth + PPI + tetracycline + metronidazole | 14 days | 85–95% | First-line in regions with clarithromycin resistance ≥15% (most of US/Europe) |
| Standard Triple | PPI + clarithromycin + amoxicillin | 14 days | 60–80% (resistance-dependent) | Only where resistance <15% + AST confirms susceptibility |
| Vonoprazan Dual (Voquezna) | Vonoprazan + amoxicillin | 14 days | ~86–93% | Antibiotic-sparing; penicillin-tolerant; preferred in Japan, growing US use |
| Concomitant (Non-bismuth Quadruple) | PPI + clarithromycin + amoxicillin + metronidazole | 14 days | 85–90% | Regions without bismuth access; requires both clarithromycin + metronidazole susceptibility |
| Rifabutin Triple (Rescue) | PPI + rifabutin + amoxicillin | 10 days | 70–80% | Third-line rescue after 2+ failures; rifabutin not affected by clarithromycin/metronidazole resistance |
H. pylori Test-and-Treat Protocol — When to Test, What to Use, and Confirmation
Who should be tested for H. pylori? ALL patients with: active peptic ulcer disease or history of ulcers; dyspepsia under age 60 without alarm symptoms (test-and-treat strategy); gastric MALT lymphoma (H. pylori eradication alone can induce remission in early-stage disease); family history of gastric cancer; currently taking NSAIDs or aspirin (H. pylori × NSAID = synergistic ulcer risk); iron deficiency anemia not otherwise explained; before starting long-term PPI therapy (PPIs suppress H. pylori activity but don't cure → untreated H. pylori in a PPI user = elevated cancer risk); TESTING: preferred non-invasive: UBT (urea breath test) or stool antigen test; hold PPI 2 weeks, antibiotics 4 weeks before testing; TREATMENT SELECTION: if no prior H. pylori treatment: bismuth quadruple (Pylera + omeprazole 20mg BID × 14 days) as first-line in the US and most of Europe; culture with AST only if available and second-line treatment is being chosen; PROBIOTIC CO-TREATMENT: start L. reuteri DSM 17938 (BioGaia) + S. boulardii (Florastor) simultaneously with antibiotics; separate by 2 hours from antibiotics; continue 4 weeks total; this improves eradication rate by ~10–13% and cuts GI side effects by 50–75%; POST-TREATMENT CONFIRMATION (MANDATORY): wait minimum 4 weeks after completing antibiotics AND 2 weeks after stopping PPI; test with UBT or stool antigen (never serology); if test is positive → retreatment with a different regimen (ideally with AST-guided antibiotic selection); WHAT TO DO AFTER SUCCESSFUL ERADICATION: successful eradication eliminates the carcinogenic bacteria but does NOT reverse existing intestinal metaplasia or atrophic gastritis if already present; patients with confirmed atrophic gastritis or intestinal metaplasia on biopsy require periodic endoscopic surveillance per gastroenterologist guidance; gastric cancer risk decreases with eradication but does not reach the level of never-infected individuals, especially in CagA+ patients; NSAID / ASPIRIN USERS: eradication before starting NSAID or aspirin therapy reduces ulcer risk by approximately 60%; for patients already on NSAIDs + H. pylori positive: eradicate + continue PPI (dual strategy reduces recurrent ulcer risk more than either alone).